Frontlight ResearchEarly access
CompletedNo phase
The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia
Key facts
- Who runs it
- Peking Union Medical College Hospital
- Where
- China4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 14 Apr 2023
- Ended
- 30 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Corticosteroids
- Corticosteroids and Ruxolitinib
- Record updated
- 28 July 2026
Who can take part
- Age
- 15 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- 18 years old≤ Aged ≤80 years old
- Diagnosis of malignancy
- Malignant tumors initially treated with immune checkpoint inhibitors (antibodies targeting PD-1, PD-L1, CTLA-4, or new immune checkpoint inhibitors) in combination with or without chemotherapy
- Diagnosis of grade 3 or 4 CIP: CIP severity at CTCAE grade 3 or 4
- Patients who and whose family members understand the study protocol, are willing to participate in the study and could provide written informed consent
Who cannot take part
- Any evidence of active or uncontrolled viral infection, including hepatitis B, hepatitis C and human immunodeficiency virus (HIV), or any clinical signs of bacterial, other viral, parasitic or fungal infection requiring treatment
- malignancy progression
- Any significant clinical and laboratory abnormalities judged by investigator that affect the safety evaluation
- Predicted life expectancy<12 weeks
- Patients with other serious complications that may affect safety or adherence judged by the investigator
- Patients can't fully understand the study protocol, arrangement and other study-related elements
- Patients with evidence of severe liver or kidney dysfunction judged by investigator unsuitable for enrolment
- Women who are pregnant, breast feeding or unable to use effective contraception during the study period and for 3 months after the completion
- Patients who cannot comply with study treatment and follow-up according to the trial protocol
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a prospective multicenter randomized controlled Interventional study, to assess the clinical efficacy and safety of corticosteroids compared to corticosteroids in combination with Ruxolitinib in the treatment of severe checkpoint inhibitor pneumonitis.
The 2 groups in the trial
- Cohort 1: severe CIP with the treatment of corticosteroidsExisting treatment, for comparison
severe CIP with the treatment of corticosteroids
Treatment: Corticosteroids
- Cohort 2: severe CIP with the treatment of corticosteroids and RuxolitinibTreatment being tested
severe CIP with the treatment of corticosteroids and Ruxolitinib
Treatment: Corticosteroids and Ruxolitinib
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Efficacy and Safety of Corticosteroids in Combination With Biological Agents in the Management of Severe Immune Related Adverse Events Cohort A: The Efficacy and Safety of Corticosteroids or Corticosteroids Combination With Ruxolitinib in Patients With Severe Checkpoint Inhibitor Pneumonia
- Record updated
- 28 July 2026